Vous souhaitez déposer une plainte contre une institution ou un organe de l’Union européenne ?
- EN English
Follow-up reply of the European Ombudsman in response to the European Medicines Agency (EMA)on how it deals with requests for public access to documents (Case 2243/2022/SF)
Correspondance - Date Vendredi | 12 juillet 2024
Affaire 2243/2022/SF - Ouvert le Mardi | 14 février 2023 - Décision le Mercredi | 13 décembre 2023 - Institution concernée Agence européenne des médicaments ( Mauvaise administration constatée ) - Pays Pays-Bas
Plainte introduite
13/12/2022Analyse de la plainte
13/12/2022Enquête en cours
11/01/2023Résultat de l’enquête
13/12/2023
|
Head of Legal Department European Medicines Agency |
Dear Mr X,
We thank you for EMA’s reply to the Ombudsman’s suggestions for improvement in the above case.
We welcome EMA’s continuous efforts to identify documents, which are of particular interest to the public and which could possibly be published proactively. We have taken note of the measures EMA has taken to phase out its chronological queue and to deal with the backlog of public access requests. We are pleased to see that these measures have already led to a decrease in the backlog.
We also note that EMA acknowledges the Ombudsman’s finding of maladministration with regard to the ‘5-2-rule’, whereby EMA limits the number of requests per applicant to five at a given time and the number of documents that can be requested at a time to two documents. However, EMA has not committed to cease applying that practice. We will therefore continue to monitor EMA’s implementation of Regulation 1049/2001 to determine whether the Ombudsman needs to pursue this matter on her own initiative.
Yours sincerely,
Rosita Hickey
Director of Inquiries
Strasbourg, 12/07/2024